Wu CY, Wu CY, Li CP, et al. - Researchers used the Taiwan National Health Insurance Database to investigate the link between bullous pemphigoid (BP) risk and dipeptidyl peptidase 4 inhibitor (DPP4i) treatment in this nationwide cohort study. They matched 1: 1 a total of 124,619 diabetic patients who were taking DPP4i therapy with diabetic patients never treated with DPP4i by age, gender, duration of diabetes, insulin use, and propensity score-matching of comorbidities. In the DPP4i-treated cohort, a significantly higher 6-year cumulative incidence of BP was reported, relative to that in the non-DPP4i group. In modified Cox regression analysis, an elevated BP risk was observed in relation to DPP4i treatment, age, renal disease, and metformin user. Findings revealed the presence of a 2.2-fold increased risk of BP among DPP4i users, and those with concomitant use of DPP4i and insulin exhibited the highest risk.